Moneycontrol Be a Pro
Get App
Last Updated : Mar 12, 2019 09:31 AM IST | Source: Moneycontrol.com

Piramal Enterprises gains after launching injection in US market

Piramal Critical Care is a global leader in anesthesia, pain management, and intrathecal therapy.

Moneycontrol News @moneycontrolcom
Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Piramal Enterprises rose 1.5 percent in the early trade on Tuesday after it launched an injection in the US market.

Piramal Critical Care, a business unit of Piramal Enterprises launched Mitigo (Morphine Sulfate Injection, USP – Preservative-free) in 10 mg/mL and 25 mg/mL concentrations in the US market.

Piramal Critical Care is a global leader in anesthesia, pain management, and intrathecal therapy.

Close

Piramal Critical Care will continue to work with wholesalers, hospitals, interventional pain doctors, and pain management centers across the country to ensure availability of MITIGO for patients with intractable chronic pain, company said in release.

Peter DeYoung, Chief Executive Officer, Piramal Critical Care said, “We are pleased to support intrathecal therapy for pain management with FDA approval and our launch of MITIGO. We continue to expand our leadership in intrathecal therapy through this launch, as well as in inhaled anesthesia and the injectable anesthesia and pain management drugs that we acquired from Janssen."

At 09:26 hrs Piramal Enterprises was quoting at Rs 2,691.40, up Rs 34.60, or 1.30 percent on the BSE.

For more market news, click here

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Mar 12, 2019 09:29 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant